Tolerability and safety
HGP1705, TEAEs
ADVERSE EVENTS, EVENTS, ADVERSE EVENT
The incidence of TEAEs was 14.3% (15/105; 22 events) in the HIP1601 group and 14.2% (15/106; 20 events) in the HGP1705 group (Table 
Summary of treatment-emergent adverse events (safety analysis set)TEAE: treatment-emergent adverse events*TEAEs: Adverse events with start date on or after administration of the study drug, or pre-existing conditions that worsened during or after study drug administration